AJP - Renal AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 266: F384-F393, 1994;
0363-6127/94 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chansel, D.
Right arrow Articles by Ardaillou, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chansel, D.
Right arrow Articles by Ardaillou, R.

AJP - Renal Physiology, Vol 266, Issue 3 384-F393, Copyright © 1994 by American Physiological Society


ARTICLES

Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells

D. Chansel, T. Bizet, S. Vandermeersch, P. Pham, B. Levy and R. Ardaillou
Institut National de la Sante et de la Recherche Medicale (INSERM) 64, Hopital Tenon, Paris, France.

The aim of the present report was to examine the effect of several agents on angiotensin II (ANG II) and losartan receptors using 125I-[Sar1,Ala8]ANG II and [3H]losartan as radiolabeled ligand, respectively. ANG II receptors were downregulated in glomeruli from rats infused with ANG II during 3 wk or rats receiving losartan orally during 1 wk. The number of sites (Bmax) was reduced, but the dissociation constant (Kd) value was unchanged. Losartan receptors were downregulated in glomeruli from rats receiving losartan, but remained unchanged in glomeruli from rats infused with ANG II. Since in vivo administration of losartan results in increase of plasma ANG II and formation of metabolites, in vitro studies using human mesangial cells were performed to better analyze the present findings. Treatment of mesangial cells during 4 days by ANG II, losartan, or its metabolite, EXP-3174, also produced downregulation of 125I-[Sar1,Ala8]ANG II binding sites with a decreased Bmax and unchanged Kd value. Only treatment of mesangial cells by ANG II or EXP-3174 produced downregulation of [3H]losartan binding sites. In contrast, exposure of these cells to losartan resulted in upregulation of [3H]losartan binding sites. Under all conditions, only Bmax was modified. Whereas internalization of [3H]losartan in mesangial cells was negligible under all experimental conditions, there was an increase of the percentage of internalized 125I-[Sar1,Ala8]ANG II after exposure of the cells to ANG II or AT1 antagonists. No change was observed in mesangial cell AT1 receptor mRNA levels. This study demonstrates that 1) AT1 mRNA is expressed in human mesangial cells; 2) the characteristics of 125I-[Sar1,Ala8]ANG II and [3H]losartan binding sites in rat glomeruli and human mesangial cells are different, with Kd and Bmax values greater in both preparations when [3H]losartan was utilized; 3) both types of binding sites obey different regulations, and the effects of losartan in vivo are due in part to the associated increase in plasma ANG II levels and the transformation of the drug into its metabolite, EXP-3174; 4) downregulation of AT1 receptors does not depend on changes in mRNA expression but is associated with increased relative internalization.


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
S. Y. Park, C. Y. Song, B. C. Kim, H. K. Hong, and H. S. Lee
Angiotensin II mediates LDL-induced superoxide generation in mesangial cells
Am J Physiol Renal Physiol, November 1, 2003; 285(5): F909 - F915.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Schwobel, T. Fischer, B. Lanz, and M. Mohaupt
Angiotensin II receptor subtypes determine induced NO production in rat glomerular mesangial cells
Am J Physiol Renal Physiol, December 1, 2000; 279(6): F1092 - F1100.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. E. Louch, G. R. Ferrier, and S. E. Howlett
Losartan Improves Recovery of Contraction and Inhibits Transient Inward Current in a Cellular Model of Cardiac Ischemia and Reperfusion
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 697 - 704.
[Abstract] [Full Text]


Home page
J. Am. Soc. Nephrol.Home page
J. WAGNER, F. GEHLEN, A. CIECHANOWICZ, and E. RITZ
Angiotensin II Receptor Type 1 Gene Expression in Human Glomerulonephritis and Diabetes Mellitus
J. Am. Soc. Nephrol., March 1, 1999; 10(3): 545 - 551.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
J. D. STOCKAND and S. C. SANSOM
Glomerular Mesangial Cells: Electrophysiology and Regulation of Contraction
Physiol Rev, July 1, 1998; 78(3): 723 - 744.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Chansel, C. Llorens-Cortes, S. Vandermeersch, P. Pham, and R. Ardaillou
Regulation of Angiotensin II Receptor Subtypes by Dexamethasone in Rat Mesangial Cells
Hypertension, April 1, 1996; 27(4): 867 - 874.
[Abstract] [Full Text]


Home page
HypertensionHome page
R. A.S. Santos, A. C. Simoes e Silva, A. J. Magaldi, M. C. Khosla, K. R. Cesar, K. T. Passaglio, and N. C.V. Baracho
Evidence for a Physiological Role of Angiotensin-(1-7) in the Control of Hydroelectrolyte Balance
Hypertension, April 1, 1996; 27(4): 875 - 884.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online